Parabilis Medicines, Inc.PBLS
ASignal's systematic analysis rates PBLS as Neutral.
Reflects the latest available analysis · analyzed Aug 19, 2026
The case on PBLS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Low debt-to-equity ratio (0.05x)
- High liquidity with current ratio of 17.91x
- MACD above signal line with expanding histogram
- Positive price momentum
- RSI at 79.34 indicating overbought conditions
- Price trading above upper Bollinger Band (potential overextension)
- Negative operating margin (-34382.43%)
- Extremely high EV/Revenue (25593.57x) and P/S (34489.14x)
- Negative operating cash flow ($-111.29M)
See the full verdict on PBLS
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes PBLS
Most investors never get a second opinion, let alone several. ASignal runs PBLS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.